For Research Use Only - Not For Human Consumption
Peptide Stores OnlineResearch Marketplace
← All FDA Peptide News
FDA AdvisoryJuly 24, 2026

FDA Advisory Committee Votes to Recommend Six Peptides for 503A Compounding List

Advisory recommendation only - not an approval

On July 23-24, 2026, the FDA convened its Pharmacy Compounding Advisory Committee for the first in a planned series of meetings evaluating peptides for the 503A bulk drug substances list. The committee voted to recommend six of seven peptides - BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon - for compounding eligibility.

The votes were notable for overriding the agency’s own scientists, who presented unanimously against all seven nominations, citing limited and underpowered studies. The committee declined only emideltide (DSIP).

Context matters: in September 2023, the FDA had placed BPC-157, TB-500, and 17 other peptides in “Category 2,” flagging safety concerns. In April 2026, following public statements from HHS Secretary Robert F. Kennedy Jr., the agency removed 12 peptides from the Category 2 list - a procedural step, not an approval.

Researchers should note what the vote was not: it was not an FDA approval, it does not change the 503A list today, and final action requires HHS sign-off plus formal rulemaking. The committee advises; the agency decides.

BPC-157KPVTB-500MOTS-cSemaxEpitalon

Sources

Frequently Asked Questions

Did the FDA approve BPC-157, TB-500, or the other peptides in July 2026?▾

No. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to RECOMMEND six peptides for the 503A bulk substances list. Committee votes are advisory and non-binding - nothing was approved and the 503A list is unchanged until FDA completes rulemaking.

Which six peptides did the committee recommend?▾

BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. The committee declined to recommend the seventh peptide under review, emideltide (DSIP).

Why was the vote controversial?▾

FDA’s own staff scientists presented against all seven peptides, citing short, underpowered studies and an absence of human clinical data for several. The committee overrode the staff position on six of seven votes.

What happens next in the process?▾

FDA is reviewing the recommendations. Final action requires HHS sign-off and a rulemaking process that typically takes the better part of a year. Until then, the regulatory status of these peptides is unchanged.

Does a compounding recommendation mean these peptides are safe or effective?▾

No. A 503A bulk-substances listing governs pharmacy compounding eligibility - it is not an FDA determination of safety or efficacy, which requires full new-drug review.

Regulatory reporting only. This article describes FDA actions on specific drug products - it is not usage guidance. Peptide Stores Online sells compounds strictly for laboratory research use, not for human consumption.

Related FDA Updates

Guides

HPLC Purity Versus Net Peptide Content: What the Numbers on a COA Mean

October 23, 2026Guides

How to Compare Research Peptide Vendors: A Buyer's Checklist

October 22, 2026Guides

Lyophilized Peptide Storage: What Published Research and Vendor Data Sheets Actually Say

October 21, 2026

All products listed on Peptide Stores Online are for in-vitro laboratory and educational research purposes only. Not for human or animal consumption. Not evaluated by the Food and Drug Administration. Not intended to diagnose, treat, cure, or prevent any disease or condition. All sellers and buyers agree to full research-use-only terms at account creation. Peptide Stores Online assumes no liability for misuse of any product listed on this platform.